The Potential Role of Platelet-Related microRNAs in the Development of Cardiovascular Events in High-Risk Populations, Including Diabetic Patients: A Review

Frontiers in Endocrinology

Ceren Eyileten¹  Katarzyna Pisarz¹  Justyna Pordzik¹  Marek Postula¹  Axel Dyve Jones¹  Salvatore De Rosa²  Lukasz Malek³  Ciro Indolfi⁴ 

[1] Center for Preclinical Research and Technology CEPT, Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Warsaw, Poland;Division of Cardiology, Department of Medical and Surgical Sciences, “Magna Graecia” University, Catanzaro, Italy;Faculty of Rehabilitation, University of Physical Education, Warsaw, Poland;URT-CNR, Department of Medicine, Consiglio Nazionale delle Ricerche of IFC, Catanzaro, Italy;

关键词: biomarker;    microRNA;    platelet microvesicles;    platelet reactivity;    cardiovascular diseases;    type 2 diabetes mellitus;   

DOI  :  10.3389/fendo.2018.00074

来源: DOAJ

【 摘 要 】

Platelet activation plays a pivotal role in the development and progression of atherosclerosis, which often leads to potentially fatal ischemic events at later stages of the disease. Platelets and platelet microvesicles (PMVs) contain large amounts of microRNA (miRNA), which contributes largely to the pool of circulating miRNAs. Hence, they represent a promising option for the development of innovative diagnostic biomarkers, that can be specific for the underlying etiology. Circulating miRNAs can be responsible for intracellular communication and may have a biological effect on target cells. As miRNAs associated to both cardiovascular diseases (CVD) and diabetes mellitus can be measured by means of a wide array of techniques, they can be exploited as an innovative class of smart disease biomarkers. In this manuscript, we provide an outline of miRNAs associated with platelet function and reactivity (miR-223, miR-126, miR-197, miR-191, miR-21, miR-150, miR-155, miR-140, miR-96, miR-98) that should be evaluated as novel biomarkers to improve diagnostics and treatment of CVD.

【 授权许可】

Unknown